Fas Ligand Induces Cell-autonomous NF-kappaB Activation and Interleukin-8 Production by a Mechanism Distinct from That of Tumor Necrosis Factor-alpha
Overview
Authors
Affiliations
Fas ligand (FasL) has been well characterized as a death factor. However, recent studies revealed that FasL possesses inflammatory activity. Here we found that FasL induces production of the inflammatory chemokine IL-8 without inducing apoptosis in HEK293 cells. Reporter gene assays involving wild-type and mutated IL-8 promoters and NF-kappaB- and AP-1 reporter constructs indicated that an FasL-induced NF-kappaB and AP-1 activity are required for maximal promoter activity. FasL induced NF-kappaB activation with slower kinetics than did TNF-alpha, yet this response was cell autonomous and not mediated by secondary paracrine factors. The death domain of Fas, FADD, and caspase-8 were required for NF-kappaB activation by FasL. A dominant-negative mutant of IKKgamma inhibited the FasL-induced NF-kappaB activation. However, TRADD and RIP, which are essential for the TNF-alpha-induced NF-kappaB activation, were not involved in the FasL-induced NF-kappaB activation. Moreover, CLARP/FLIP inhibited the FasL- but not the TNF-alpha-induced NF-kappaB activation. These results show that FasL induces NF-kappaB activation and IL-8 production by a novel mechanism, distinct from that of TNF-alpha. In addition, we found that mouse FADD had a dominant-negative effect on the FasL-induced NF-kappaB activation in HEK293 cells, which may indicate a species difference between human and mouse in the FasL-induced NF-kappaB activation.
The Crosstalk of Apoptotic and Non-Apoptotic Signaling in CD95 System.
Seyrek K, Espe J, Reiss E, Lavrik I Cells. 2024; 13(21.
PMID: 39513921 PMC: 11545656. DOI: 10.3390/cells13211814.
Molluscum Contagiosum Virus: Biology and Immune Response.
Santacroce L, Magrone T Adv Exp Med Biol. 2024; 1451:151-170.
PMID: 38801577 DOI: 10.1007/978-3-031-57165-7_10.
TNF-Related Apoptosis-Inducing Ligand: Non-Apoptotic Signalling.
Guerrache A, Micheau O Cells. 2024; 13(6.
PMID: 38534365 PMC: 10968836. DOI: 10.3390/cells13060521.
Shen C, Chan R, Lin B, Li N, Huang Y, Chang W Theranostics. 2023; 13(13):4650-4666.
PMID: 37649607 PMC: 10465226. DOI: 10.7150/thno.85855.
Therapeutic approaches targeting CD95L/CD95 signaling in cancer and autoimmune diseases.
Risso V, Lafont E, Le Gallo M Cell Death Dis. 2022; 13(3):248.
PMID: 35301281 PMC: 8931059. DOI: 10.1038/s41419-022-04688-x.